KRAS and neoplasm: A large-scale study conducted by our group previously reported similar cytotoxic effects to other tumor types, such as melanoma, pancreas esophagus cell lines, where the majority (70%) of the KRAS mutant cell lines were classified as allitinib resistant [13].